Develops miniprotein radioconjugate drug candidates that deliver radioactive medicines to solid tumors for cancer patients.
10-K, filed Mar 30, 2026We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient…View ↗
We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy to a broad range of…View ↗
Our platform capabilities have generated a pipeline of several novel product candidates. Our most advanced program is a radiopharmaceutical…View ↗
Eli Lilly works directly with Aktis under a strategic collaboration to develop radioconjugates outside Aktis’ proprietary pipeline.
8-K, filed Apr 16, 2026 10-K, filed Mar 30, 2026Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals…View ↗
Since our inception in August 2020, we have devoted substantially all of our resources to developing our miniprotein radioconjugate…View ↗
Competes with Abdera Therapeutics, Actinium Pharmaceuticals, Alpha9 Oncology, Artbio, Bayer, Convergent Therapeutics, Fusion Pharmaceuticals, Johnson & Johnson, Mariana Oncology, Perspective Therapeutics, POINT Biopharma Global, RadioMedix, Radionetics Oncology, RayzeBio, Telix Pharmaceuticals, Lantheus Holdings, Novartis, Sirtex, Boston Scientific, and Q BioMed
10-K, filed Mar 30, 2026We consider our most direct competitors to be companies developing targeted alpha-based radiopharmaceuticals for the treatment of cancer.…View ↗
Loading...